Misplaced Pages

Oxotremorine: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 19:01, 6 September 2010 editYobot (talk | contribs)Bots4,733,870 editsm →References: WP:CHECKWIKI error fixes + genfixes using AWB (7092)← Previous edit Latest revision as of 04:14, 26 October 2024 edit undo76.174.0.57 (talk) Tweaks. 
(52 intermediate revisions by 28 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
⚫ {{drugbox | Watchedfields = changed
{{Drugbox
⚫ | verifiedrevid = 261862121
| Verifiedfields = changed
|
⚫ | Watchedfields = changed
⚫ | IUPAC_name = 1-(4-pyrrolidin- 1-ylbut- 2-yn- 1-yl) pyrrolidin- 2-one
⚫ | verifiedrevid = 383299199
⚫ | image = Oxotremorine.png
⚫ | IUPAC_name = 1-(4-Pyrrolidin-1-ylbut-2-yn-1-yl)pyrrolidin-2-one
⚫ | image = Oxotremorine.svg
| width = 200 | width = 200
<!--Clinical data-->
| CASNo_Ref = {{cascite}}
| tradename =
| pregnancy_US =
| pregnancy_category = C
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US_comment = Experimental/not yet approved
⚫ | routes_of_administration = Oral, intravenous
<!--Pharmacokinetic data-->
⚫ | bioavailability =
⚫ | protein_bound =
⚫ | metabolism =
⚫ | elimination_half-life =
⚫ | excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 70-22-4 | CAS_number = 70-22-4
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5RY0UWH1JL
| ATC_prefix = none | ATC_prefix = none
| ATC_suffix = | ATC_suffix =
| PubChem = | PubChem =
| IUPHAR_ligand = 302 | IUPHAR_ligand = 302
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = | DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4469
| KEGG =
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 7634
<!--Chemical data-->
| C=12 | H=18 | N=2 | O=1 | C=12 | H=18 | N=2 | O=1
| smiles = C1CCN(C1)CC#CCN2CCCC2=O
| molecular_weight = 206.28
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
⚫ | bioavailability =
| StdInChI = InChI=1S/C12H18N2O/c15-12-6-5-11-14(12)10-4-3-9-13-7-1-2-8-13/h1-2,5-11H2
⚫ | protein_bound =
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
⚫ | metabolism =
| StdInChI_comment =
⚫ | elimination_half-life =
| StdInChIKey = RSDOPYMFZBJHRL-UHFFFAOYSA-N
⚫ | excretion =
| density =
| pregnancy_AU =
| pregnancy_US = | melting_point =
| pregnancy_category = | melting_high =
| legal_AU = | melting_notes =
| legal_CA = | boiling_point =
| legal_UK = | boiling_notes =
| legal_US = | solubility =
| specific_rotation =
| legal_status =
| sec_combustion =
| dependency_liability
⚫ | routes_of_administration =
}} }}


'''Oxotremorine''' is a ] that acts as a non-selective ] ].<ref name="pmid8330013">{{cite journal |author=Tang C, Castoldi AF, Costa LG |title=Effects of the muscarinic agonist oxotremorine on membrane fluidity in rat lymphocytes |journal=Biochem. Mol. Biol. Int. |volume=29 |issue=6 |pages=1047–54 |year=1993 |month=April |pmid=8330013 |doi= |url=}}</ref> '''Oxotremorine''' is a drug that acts as a selective ] ].<ref name="pmid8330013">{{cite journal | vauthors = Tang C, Castoldi AF, Costa LG | title = Effects of the muscarinic agonist oxotremorine on membrane fluidity in rat lymphocytes | journal = Biochemistry and Molecular Biology International | volume = 29 | issue = 6 | pages = 1047–54 | date = April 1993 | pmid = 8330013 | id = {{INIST|4025194}} }}</ref>


Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs.<ref>Craig, C. R., Stitzel, R. E., Modern Pharmacology. Little, Brown. Boston, 2006.</ref> Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs.<ref>{{cite book | veditors = Craig CR, Stitzel RE |title=Modern Pharmacology with Clinical Applications |date=2004 |publisher=Lippincott Williams & Wilkins |isbn=978-0-7817-3762-3 }}{{pn|date=January 2021}}</ref>


Oxotremorine also produces ]-like effects.<ref>{{cite journal | vauthors = Maehara S, Hikichi H, Satow A, Okuda S, Ohta H | title = Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia | journal = Pharmacology, Biochemistry, and Behavior | volume = 91 | issue = 1 | pages = 140–9 | date = November 2008 | pmid = 18651995 | doi = 10.1016/j.pbb.2008.06.023 | s2cid = 12225821 | id = {{INIST|20678587}} }}</ref>
⚫ == References ==
⚫ {{Reflist|2}}


== See also ==
{{Cholinergics}}
* ]


⚫ == References ==
⚫ ]
⚫ {{Reflist}}
⚫ ]
⚫ ]


{{Muscarinic acetylcholine receptor modulators}}


⚫ ]
{{pharmacology-stub}}
⚫ ]
]
]
]
]
]
⚫ ]


{{nervous-system-drug-stub}}
]
]

Latest revision as of 04:14, 26 October 2024

Chemical compound Pharmaceutical compound
Oxotremorine
Clinical data
Pregnancy
category
  • C
Routes of
administration		Oral, intravenous
ATC code
  • none
Legal status
Legal status
  • US: Experimental/not yet approved
Identifiers
IUPAC name
  • 1-(4-Pyrrolidin-1-ylbut-2-yn-1-yl)pyrrolidin-2-one
CAS Number
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.000.662 Edit this at Wikidata
Chemical and physical data
FormulaC12H18N2O
Molar mass206.289 g·mol
3D model (JSmol)
SMILES
  • C1CCN(C1)CC#CCN2CCCC2=O
InChI
  • InChI=InChI=1S/C12H18N2O/c15-12-6-5-11-14(12)10-4-3-9-13-7-1-2-8-13/h1-2,5-11H2
  • Key:RSDOPYMFZBJHRL-UHFFFAOYSA-N
  (what is this?)  (verify)

Oxotremorine is a drug that acts as a selective muscarinic acetylcholine receptor agonist.

Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs.

Oxotremorine also produces antipsychotic-like effects.

See also

References

  1. Tang C, Castoldi AF, Costa LG (April 1993). "Effects of the muscarinic agonist oxotremorine on membrane fluidity in rat lymphocytes". Biochemistry and Molecular Biology International. 29 (6): 1047–54. PMID 8330013. INIST 4025194.
  2. Craig CR, Stitzel RE, eds. (2004). Modern Pharmacology with Clinical Applications. Lippincott Williams & Wilkins. ISBN 978-0-7817-3762-3.
  3. Maehara S, Hikichi H, Satow A, Okuda S, Ohta H (November 2008). "Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia". Pharmacology, Biochemistry, and Behavior. 91 (1): 140–9. doi:10.1016/j.pbb.2008.06.023. PMID 18651995. S2CID 12225821. INIST 20678587.
Muscarinic acetylcholine receptor modulators
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Nicotinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators
Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories:
Oxotremorine: Difference between revisions Add topic